Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS. Nyquist MD, et al. Among authors: dalton jt. J Clin Invest. 2021 May 17;131(10):e146777. doi: 10.1172/JCI146777. J Clin Invest. 2021. PMID: 33998604 Free PMC article.
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS. Nyquist MD, et al. Among authors: dalton jt. J Clin Invest. 2021 Jun 15;131(12):e151719. doi: 10.1172/JCI151719. J Clin Invest. 2021. PMID: 34128479 Free PMC article. No abstract available.
Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, Dalton JT, Miller DD, Narayanan R. Ponnusamy S, et al. Among authors: dalton jt. Cancer Res. 2017 Nov 15;77(22):6282-6298. doi: 10.1158/0008-5472.CAN-17-0976. Epub 2017 Oct 4. Cancer Res. 2017. PMID: 28978635 Free PMC article.
Development of selective androgen receptor modulators (SARMs).
Narayanan R, Coss CC, Dalton JT. Narayanan R, et al. Among authors: dalton jt. Mol Cell Endocrinol. 2018 Apr 15;465:134-142. doi: 10.1016/j.mce.2017.06.013. Epub 2017 Jun 15. Mol Cell Endocrinol. 2018. PMID: 28624515 Free PMC article. Review.
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT. Crawford J, et al. Among authors: dalton jt. Curr Oncol Rep. 2016 Jun;18(6):37. doi: 10.1007/s11912-016-0522-0. Curr Oncol Rep. 2016. PMID: 27138015 Free PMC article. Review.
170 results